Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Peanut Allergy Treatment Market

Peanut Allergy Treatment Market Share

Report ID: GMI10199
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Peanut Allergy Treatment Market Share

The market for peanut allergy treatment is concentrated due to the requirement of high initial capital investments for developing therapeutic candidate. Moreover, uncertainty towards the success of therapy during clinical trials exposes smaller vendors to a high risk of financial losses, limiting their entry into the market. On the other hand, established vendors have significant expertise and financial resources to develop and commercialize new therapeutic candidates.

The market is witnessing a limited availability of approved and commercialized immunotherapy products that are indicated for treating peanut allergy. The vendors have significant number of products currently in pipeline stage, and the competition is more focused towards gaining an early entry into the market.

Peanut Allergy Treatment Market Companies

Prominent players operating in the peanut allergy treatment industry include:

Adamis Pharmaceuticals Corporation
AdvaCare Pharma
Aimmune Therapeutics Inc.
Amneal Pharmaceuticals LLC
Amphastar Pharmaceuticals, Inc.
CVS Pharmacy
DBV Technologies
Grand Pharma (China) Co., Ltd.
Kaleo
Mylan N.V.
Novartis AG
Regeneron Pharmaceuticals Inc.
Sanofi
TerSera Therapeutics LLC
Teva Pharmaceuticals Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Peanut allergy treatment industry size was worth USD 483.5 million in 2023 and is projected to expand at 12.1% CAGR from 2024 to 2032, due to growing prevalence of peanut allergies, and increasing investments for developing new treatment modalities.

The injectable route of administration segment in the peanut allergy treatment industry accounted for 51.4% share in 2023 as they find extensive use in delivering epinephrine and immunotherapeutic treatments such as Dupixent.

The epinephrine drug class segment in the peanut allergy treatment industry accounted for USD 233 million in 2023 owing to drug ability to reverse any life-threatening symptoms such as swelling of the airway and low blood pressure.

North America peanut allergy treatment industry accounted for 41.3% share in 2023 and is projected to expand at substantial rate from 2024 to 2032, led by the increasing prevalence of peanut allergies in the region.